Peptide Synthesis Market by Instruments (Synthesizers, Purification, Lyophilizers, Analytical), Reagents (Amino Acids, Resins), Technique (Chemical, Biological), Services (Custom Synthesis, Modification), Application, End User - Global Forecast to 2031

Market Size
$0.98B
MARKET SIZE, 2026
Projected Market Size
$1.54B
MARKET SIZE, 2031
CAGR
9.5%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

PEPTIDE SYNTHESIS MARKET SIZE, SHARE & GROWTH SNAPSHOT

peptide-synthesis-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global peptide synthesis market is projected to grow from USD 0.98 billion in 2026 to USD 1.54 billion by 2031, at a CAGR of 9.5% during the forecast period. The market was valued at USD 0.91 billion in 2025. Growth in the peptide synthesis market is driven by the expanding peptide therapeutics pipeline, rapidly rising demand for GLP-1 and other metabolic peptides, increasing development of peptide-drug conjugates and oncology therapies, and growing use of complex and modified peptides in drug discovery. The market is further supported by rising pharmaceutical & biotechnology R&D expenditure, increased outsourcing of custom peptide synthesis, and technological advances in automated and high-throughput solid-phase peptide synthesis, microwave-assisted synthesis, advanced purification and analytical technologies, greener synthesis chemistries, and improved peptide modification workflows.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2025): USD 0.91 Billion
    Current Market Size (2026): USD 0.98 Billion
    Forecast Market Size (2031): USD 1.54 Billion
    CAGR (2026–2031): 9.5%
  • SEGMENT LEADERSHIP:
    Regional Leader: North America accounted for the largest share of ~41.8% of the market in 2025.
    Offering Leader: Services segment is projected to register the highest CAGR of 12.0% in the peptide synthesis market during the forecast period.
    Product Type Leader: Reagents & consumables segment accounted for the largest share of 71.4% of the peptide synthesis products market in 2025.
    Technique Leader: Biological synthesis is projected to register the highest CAGR in the peptide synthesis products market during the forecast period.
    Product End User Leader: Pharmaceutical & biotechnology companies accounted for the largest share of the peptide synthesis products market in 2025.
    Service Type Leader: Custom peptide synthesis services segment accounted for the largest share of the market in 2025.
    Service End User Leader: CROs & CDMOs are projected to register the highest CAGR in the peptide synthesis services market during the forecast period.
    Application Leader: Therapeutic applications accounted for the largest share of the peptide synthesis market in 2025.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., GenScript Biotech Corporation, and Kaneka Corporation were identified as star players in the global peptide synthesis market, given their strong market presence, broad product & service portfolios, and extensive geographic footprint.
    JPT Peptide Technologies GmbH, LifeTein LLC, Creative Peptides, and AAPPTec, LLC have distinguished themselves among startups and SMEs through specialized peptide synthesis capabilities, complex peptide modifications, peptide libraries, and niche synthesis technologies, underscoring their potential as emerging market leaders.

The peptide synthesis market is expected to grow steadily over the forecast period, supported by the expanding pipeline of peptide-based therapeutics, increasing demand for GLP-1 and other metabolic peptides, and growing use of complex and modified peptides in drug discovery. Growth is further driven by rising pharmaceutical and biotechnology R&D expenditure, greater outsourcing of custom peptide synthesis, and increasing adoption of automated and high-throughput synthesis platforms. Advances in solid-phase peptide synthesis, peptide engineering, purification, analytical characterization, and greener synthesis chemistries are further strengthening demand across pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic applications.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact of customer-side business trends in the peptide synthesis market is shaped by expanding peptide therapeutics pipelines, rising demand for GLP-1-based drugs, and increasing outsourcing of custom peptide synthesis. Key trends include wider adoption of automated and high-throughput synthesis, growing demand for complex and modified peptides, and greater focus on rapid turnaround and quality consistency. Greener chemistries, improved purification workflows, supply-chain resilience, and evolving sustainability requirements are also influencing purchasing decisions and supplier selection.

peptide-synthesis-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Surging demand for GLP-1 and other high-volume peptide therapeutics
  • Rising complexity of peptide modalities requiring advanced synthesis and purification
RESTRAINTS
Impact
Level
  • High material consumption and waste generation in large-scale peptide synthesis
  • High cost and supply sensitivity of GMP-grade synthesis inputs
OPPORTUNITIES
Impact
Level
  • Rapid expansion of global GMP peptide manufacturing capacity
  • Shift toward continuous-flow, hybrid, and solvent-efficient peptide synthesis technologies
CHALLENGES
Impact
Level
  • Maintaining yield, purity, and batch consistency for complex peptides at scale

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Surging demand for GLP-1 and other high-volume peptide therapeutics

Rapid growth in GLP-1 receptor agonists and other peptide-based therapeutics is significantly increasing demand across the peptide synthesis ecosystem. Expanding development pipelines in obesity, diabetes, oncology, cardiovascular diseases, and other therapeutic areas are driving greater consumption of protected amino acids, resins, coupling reagents, solvents, and purification consumables. Rising peptide complexity is also increasing requirements for automated synthesizers, high-throughput platforms, advanced purification systems, and analytical technologies. Pharmaceutical & biotechnology companies are simultaneously expanding research programs and outsourcing specialized peptide synthesis activities to address capacity constraints and technical complexity. Continued innovation in long-acting peptides, conjugates, cyclic peptides, and multi-agonist molecules is expected to sustain demand for efficient synthesis technologies and high-quality synthesis inputs.

Restraint: High cost and supply sensitivity of GMP-grade synthesis inputs

Peptide synthesis relies on specialized raw materials, including high-purity protected amino acids, resins, coupling reagents, solvents, and peptide modification reagents, several of which carry relatively high procurement costs. Requirements for stringent purity, traceability, impurity control, and documentation further increase the cost of GMP-grade inputs. Supply disruptions or limited availability of specific amino acid derivatives and specialty reagents can affect synthesis timelines and increase inventory requirements. These pressures are particularly relevant for complex peptides requiring multiple coupling cycles or non-standard building blocks. High solvent and reagent consumption also raises operating costs and waste-management requirements. Consequently, input cost volatility and supply-chain sensitivity can constrain broader adoption and place additional pressure on peptide developers and synthesis service providers.

Opportunity: Rapid expansion of global GMP peptide manufacturing capacity

Global investment in peptide manufacturing capacity is creating significant opportunities for suppliers of peptide synthesis instruments, reagents, consumables, purification technologies, and analytical solutions. Rising commercial demand for GLP-1 receptor agonists and other peptide therapeutics has encouraged pharmaceutical companies and peptide manufacturers to expand facilities and install higher-capacity synthesis and purification infrastructure. These investments increase requirements for automated synthesizers, chromatography systems, protected amino acids, resins, reagents, solvents, and quality-control technologies. Capacity additions in North America, Europe, and Asia Pacific are also strengthening regional peptide supply chains and encouraging adoption of more efficient and sustainable synthesis workflows. Although commercial manufacturing services are outside the market scope, expansion of manufacturing infrastructure directly supports demand for peptide synthesis products and associated research-scale services covered in the market.

Challenge: Maintaining yield, purity, and batch consistency for complex peptides at scale

Increasing peptide length, hydrophobicity, aggregation tendency, and structural complexity can create significant synthesis and purification challenges. Incomplete coupling, deletion sequences, racemization, side reactions, and difficult deprotection steps may reduce overall yield and increase impurity levels, particularly for cyclic, conjugated, modified, and long peptides. Maintaining consistent quality becomes more difficult as synthesis volumes increase because small inefficiencies can accumulate across multiple reaction cycles. Purification of closely related peptide impurities can also require extensive chromatography and analytical characterization, increasing material consumption, processing time, and cost. Suppliers are therefore focusing on improved resins, coupling chemistries, automated process control, advanced purification technologies, and analytical methods to improve reproducibility. Achieving high purity and consistent performance while controlling cost remains a key technical challenge.

PEPTIDE SYNTHESIS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
 Has worked with GenScript Biotech Corporation (China) to generate thousands of peptides used to study T-cell receptor recognition and identify novel targets for solid-tumor therapeutics. Enabled large-scale generation of diverse peptide libraries required for target discovery, supporting identification of tumor-specific targets and development of potentially safer and more effective T-cell receptor therapies.
company logo
 Uses Biotage AB (Sweden) peptide synthesis and downstream processing technologies, including Syro automated peptide synthesizers, Initiator+ microwave systems, Isolera purification systems, and V-10 evaporation systems, within its peptide drug-discovery workflows. Parallel synthesis increased peptide throughput, while heated synthesis shortened coupling times for certain reactions from around one hour to about 10 minutes. The integrated workflow also supports difficult sequences, faster purification, and expansion of peptide discovery programs.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The ecosystem comprises pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic laboratories as primary end users. Key suppliers include manufacturers of peptide synthesizers, chromatography systems, purification equipment, protected amino acids, resins, coupling reagents, solvents, and other synthesis consumables, along with custom peptide synthesis service providers. Raw material suppliers, distributors, analytical technology providers, engineering firms, regulatory authorities, and research organizations support product development, synthesis optimization, quality control, and technology adoption. These stakeholders collaborate to advance peptide therapeutics, diagnostics, and research applications while improving synthesis efficiency, peptide purity, automation, sequence complexity handling, supply reliability, sustainability, and turnaround time.

peptide-synthesis-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

peptide-synthesis-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Peptide Synthesis Market, by Offering

In 2025, the products segment accounted for the largest market share, supported by recurring demand for peptide synthesis instruments, reagents, and consumables across research and therapeutic development workflows. Repeated consumption of protected amino acids, resins, coupling reagents, solvents, and other synthesis chemicals creates a strong recurring revenue base. Demand is further supported by increasing adoption of automated peptide synthesizers, purification systems, and analytical instruments across pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes.

Peptide Synthesis Products Market, by Product Type

In 2025, reagents and consumables dominated the peptide synthesis products market because they are used in every synthesis cycle. Protected amino acids, resins, coupling and deprotection reagents, solvents, and peptide modification reagents are essential for producing peptides with varying lengths, structures, and purity requirements. Growing development of complex, cyclic, conjugated, and modified peptides further increases material consumption. Their high replacement frequency compared with capital equipment and broad utilization across research and therapeutic development workflows continue to support the segment’s dominant position.

Peptide Synthesis Market, by Technique

In 2025, chemical synthesis dominated the market, driven primarily by the widespread adoption of solid-phase peptide synthesis for research and therapeutic peptide production. Chemical synthesis offers flexibility in sequence design, incorporation of non-natural amino acids, and introduction of structural modifications required for complex peptides. Its established workflows, broad reagent availability, automation compatibility, and suitability for short- to medium-length peptides support extensive adoption. Continued advancements in coupling chemistry, resins, automation, and greener solvents are further improving synthesis efficiency, yield, and reproducibility.

Peptide Synthesis Services Market, by Type

In 2025, custom peptide synthesis accounted for the largest share of the peptide synthesis services market, supported by increasing outsourcing of research-scale peptide requirements by pharmaceutical & biotechnology companies, CROs, and academic institutions. Demand spans crude, desalted, high-purity, modified, long, and library peptides used across drug discovery, assay development, biomarker research, and other applications. Growth is further supported by rising requirements for difficult sequences, rapid turnaround, specialized modifications, and consistent purity. Peptide engineering & modification, purification, labeling, and analytical services are also gaining importance as peptide candidates become more structurally complex and application-specific.

Peptide Synthesis Market, by Application

In 2025, therapeutic applications accounted for the largest share of the peptide synthesis market, supported by the expanding pipeline and commercialization of peptide-based drugs across metabolic disorders, oncology, infectious diseases, and other therapeutic areas. Rising demand for GLP-1 receptor agonists and other peptide hormones is significantly increasing peptide research and development activity. Growing interest in peptide-drug conjugates, targeted peptides, and modified therapeutic peptides is further strengthening demand for synthesis products and services with high purity, sequence complexity, and specialized modification capabilities.

REGION

Asia Pacific to be fastest-growing region in global peptide synthesis market during forecast period

The Asia Pacific region is expected to register the fastest growth in the peptide synthesis market during the forecast period. Growth is supported by expanding pharmaceutical and biotechnology R&D, increasing peptide drug discovery, rising outsourcing of custom peptide synthesis, and growing research activity across China, India, Japan, South Korea, and Australia. The region also benefits from comparatively lower operating costs, expanding CRO capabilities, government support for biotechnology innovation, and increasing adoption of automated peptide synthesis and advanced purification technologies. Rising development of metabolic, oncology, antimicrobial, and other peptide therapeutics is further strengthening demand for synthesizers, protected amino acids, resins, reagents, solvents, and analytical solutions. Growing focus on sustainable synthesis methods and high-throughput research workflows is expected to further support market expansion.

peptide-synthesis-market Region

PEPTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX

The company evaluation matrix provides information on the top 20 players offering peptide synthesis products and services and outlines each vendor’s performance. In the peptide synthesis market, Thermo Fisher Scientific Inc. (US) leads with a broad product footprint spanning synthesis reagents, consumables, purification, analytical solutions, and custom peptide services. Biotage AB (Sweden) (Emerging Leader) is gaining traction through its expanding portfolio of automated peptide synthesis, microwave-assisted synthesis, purification, and sample-processing technologies, supported by continued product innovation and growing penetration in peptide research workflows.

peptide-synthesis-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 0.91 Billion
Market Forecast in 2026 (Value) USD 0.98 Billion
Market Forecast in 2031 (Value) USD 1.54 Billion
Growth Rate CAGR of 9.5% from 2026–2031
Years Considered 2024–2031
Base Year 2025
Forecast Period 2026–2031
Units Considered Value (USD Million/Billion)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends
Segments Covered
  • By Offering:
    • Products
    • Services
  • By Product Type:
    • Instruments
    • Reagents & Consumables
  • By Technique:
    • Chemical Synthesis
    • Biological Synthesis
  • By Service Type:
    • Custom Peptide Synthesis Services
    • Peptide Engineering & Modification Services
    • Peptide Purification Services
    • Peptide Analytical & Characterization Services
    • Peptide Library Preparation/Synthesis Services
  • By Application:
    • Therapeutic Applications
    • Diagnostics Applications
    • Research Applications
  • By Product End User:
    • Pharmaceutical & Biotechnology Companies
    • CROs & CDMOs
    • Academic & Research Institutes
    • Medical Device Companies
    • Clinical & Diagnostic Laboratories
  • By Service End User:
    • Pharmaceutical & Biotechnology Companies
    • CROs & CDMOs
    • Academic & Research Institutes
    • Medical Device Companies
    • Clinical & Diagnostic Laboratories
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa

WHAT IS IN IT FOR YOU: PEPTIDE SYNTHESIS MARKET REPORT CONTENT GUIDE

peptide-synthesis-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
India GLP-1 Agonist Market Assessment
  • India GLP-1 agonist market estimation and forecast, by molecule and indication
  • Competitive landscape and key marketed products
  • Pricing analysis and adoption trends
  • Enables India-specific market entry and commercialization planning
  • Helps assess molecule-level demand, competitive positioning, and pricing opportunities
  • Supports launch strategy and identification of high-potential patient and customer segments
Peptide Therapeutics Pipeline and Future Synthesis Demand Analysis
  • Pipeline analysis of peptide therapeutics by phase, indication, molecule type, and sponsor
  • Expected launch timelines and pipeline progression across major regions
  • Assessment of future peptide synthesis requirements linked to advancing pipeline assets
  • Identifies high-potential pipeline products and future growth opportunities
  • Helps anticipate demand for peptide synthesis products and services
  • Supports capacity planning, account targeting, and strategic expansion decisions

RECENT DEVELOPMENTS

  • July 2026 : Agilent Technologies, Inc. (US) expanded its Altura HPLC column portfolio with new Ultra Inert SEC and PLRP-S columns for biotherapeutic analysis. The columns support peptide workflows, including GLP-1 therapeutics, by improving aggregate characterization, impurity detection, peak shape, and analytical sensitivity.
  • April 2026 : Bachem Holding AG (Switzerland) opened Building K at its Bubendorf, Switzerland site to expand industrial-scale production of peptide and oligonucleotide active ingredients. The facility is a part of Bachem’s broader capacity-expansion program and is intended to address rising global demand for peptide-based therapeutics.
  • June 2025 : CEM Corporation (US) launched the Prodigy 2.0 preparative HPLC system for synthetic peptide purification. The system uses elevated-temperature purification to improve peptide recovery and enables ethanol to replace acetonitrile, supporting more efficient and sustainable peptide purification workflows.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
59
2
EXECUTIVE SUMMARY
 
 
 
 
 
65
3
PREMIUM INSIGHTS
 
 
 
 
 
71
4
MARKET OVERVIEW
Unlock growth by leveraging advanced synthesis technologies amid surging peptide therapeutic demand.
 
 
 
 
 
75
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
SURGING DEMAND FOR GLP-1 AND OTHER HIGH-VOLUME PEPTIDE THERAPEUTICS
 
 
 
 
 
 
4.2.1.2
RISING COMPLEXITY OF PEPTIDE MODALITIES REQUIRING ADVANCED SYNTHESIS AND PURIFICATION
 
 
 
 
 
 
4.2.1.3
EXPANDING PEPTIDE DRUG PIPELINES AND CLINICAL DEVELOPMENT ACTIVITY
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
HIGH MATERIAL CONSUMPTION AND WASTE GENERATION IN LARGE-SCALE SOLID-PHASE PEPTIDE SYNTHESIS
 
 
 
 
 
 
4.2.2.2
HIGH COST AND SUPPLY SENSITIVITY OF GMP-GRADE SYNTHESIS INPUTS
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
RAPID EXPANSION OF GLOBAL GMP PEPTIDE MANUFACTURING CAPACITY
 
 
 
 
 
 
4.2.3.2
SHIFT TOWARD CONTINUOUS-FLOW, HYBRID, AND SOLVENT-EFFICIENT PEPTIDE SYNTHESIS TECHNOLOGIES
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
MAINTAINING YIELD, PURITY, AND BATCH CONSISTENCY FOR COMPLEX PEPTIDES AT SCALE
 
 
 
 
4.3
UNMET NEEDS & WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
Navigate market shifts with strategic insights into competitive forces and pricing dynamics.
 
 
 
 
 
83
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.2
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.3
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.4
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS & FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL PEPTIDE SYNTHESIS MARKET
 
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
 
 
 
 
 
 
5.5.2
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION
 
 
 
 
 
5.6
TRADE ANALYSIS
 
 
 
 
 
 
 
 
5.6.1
IMPORT SCENARIO (HS CODE 902720)
 
 
 
 
 
 
5.6.2
EXPORT SCENARIO (HS CODE 902720)
 
 
 
 
 
 
5.6.3
IMPORT SCENARIO (HS CODE 841933)
 
 
 
 
 
 
5.6.4
EXPORT SCENARIO (HS CODE 841933)
 
 
 
 
 
5.7
KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
5.9
INVESTMENT & FUNDING ACTIVITY
 
 
 
 
 
 
5.10
IMPACT OF 2025 US TARIFFS ON PEPTIDE SYNTHESIS MARKET
 
 
 
 
 
 
 
 
5.10.1
INTRODUCTION
 
 
 
 
 
 
5.10.2
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.10.3
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.10.3.1
NORTH AMERICA
 
 
 
 
 
 
5.10.3.2
EUROPE
 
 
 
 
 
 
5.10.3.3
ASIA PACIFIC
 
 
 
 
 
5.10.4
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.10.4.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
5.10.4.2
CROS & CDMOS
 
 
 
 
 
 
5.10.4.3
ACADEMIC & RESEARCH INSTITUTES, DIAGNOSTIC LABS, AND OTHER END USERS
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS
AI-driven innovations revolutionize peptide synthesis, transforming market dynamics and patent landscapes.
 
 
 
 
 
105
 
6.1
TECHNOLOGY ANALYSIS
 
 
 
 
 
 
 
6.1.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1.1
SOLID-PHASE PEPTIDE SYNTHESIS (SPPS)
 
 
 
 
 
 
6.1.1.2
LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS)
 
 
 
 
 
 
6.1.1.3
ENZYMATIC PEPTIDE SYNTHESIS
 
 
 
 
 
 
6.1.1.4
RECOMBINANT PEPTIDE SYNTHESIS
 
 
 
 
 
 
6.1.1.5
CONTINUOUS-FLOW PEPTIDE SYNTHESIS
 
 
 
 
 
6.1.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.1.2.1
ANALYTICAL CHARACTERIZATION & QUALITY-CONTROL TECHNOLOGIES
 
 
 
 
 
 
6.1.2.2
PURIFICATION & DOWNSTREAM PROCESSING TECHNOLOGIES
 
 
 
 
 
 
6.1.2.3
PEPTIDE LIGATION TECHNOLOGIES
 
 
 
 
 
6.1.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.1.3.1
PROTEIN DESIGN & ENGINEERING
 
 
 
 
 
 
6.1.3.2
SYNTHETIC BIOLOGY/GENETIC-CODE ENGINEERING
 
 
 
 
6.2
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.3
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.3.1
TOP APPLICANTS/OWNERS (COMPANIES) FOR PEPTIDE SYNTHESIS PATENTS
 
 
 
 
 
6.4
FUTURE APPLICATIONS
 
 
 
 
 
 
6.5
IMPACT OF AI/GEN AI ON PEPTIDE SYNTHESIS MARKET
 
 
 
 
 
 
 
 
6.5.1
BEST PRACTICES IN PEPTIDE SYNTHESIS WORKFLOW
 
 
 
 
 
 
6.5.2
CASE STUDIES OF AI IMPLEMENTATION IN PEPTIDE SYNTHESIS MARKET
 
 
 
 
 
 
6.5.3
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
 
 
 
 
 
 
 
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PEPTIDE
 
 
 
 
7
SUSTAINABILITY & REGULATORY LANDSCAPE
Navigate complex global regulations and sustainability initiatives to drive compliance and eco-innovation.
 
 
 
 
 
117
 
7.1
REGIONAL REGULATIONS & COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
REGULATORY FRAMEWORK
 
 
 
 
 
 
7.1.3
INDUSTRY STANDARDS
 
 
 
 
 
7.2
SUSTAINABILITY INITIATIVES
 
 
 
 
 
 
7.3
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
 
 
 
 
 
 
7.4
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock strategic insights into buyer dynamics, stakeholder influence, and unmet market needs.
 
 
 
 
 
124
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.2.2
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.4
UNMET NEEDS FROM END USERS
 
 
 
 
 
 
8.5
MARKET PROFITABILITY
 
 
 
 
 
9
PEPTIDE SYNTHESIS MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 15 Data Tables
 
 
 
 
 
129
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
PRODUCTS
 
 
 
 
 
 
 
9.2.1
IN-HOUSE WORKFLOW CONTROL AND RECURRING PEPTIDE-SPECIFIC DEMAND TO DRIVE MARKET GROWTH
 
 
 
 
 
9.3
SERVICES
 
 
 
 
 
 
 
9.3.1
GROWING OUTSOURCING OF COMPLEX AND VARIABLE-VOLUME PEPTIDE PROJECTS TO SUPPORT MARKET GROWTH
 
 
 
 
10
PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 173 Data Tables
 
 
 
 
 
138
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
REAGENTS & CONSUMABLES
 
 
 
 
 
 
 
10.2.1
REAGENTS
 
 
 
 
 
 
 
10.2.1.1
AMINO ACID BUILDING BLOCKS
 
 
 
 
 
 
 
 
10.2.1.1.1
EXPANDING USE OF PROTECTED AND NON-NATURAL RESIDUES TO DRIVE DEMAND FOR AMINO ACID BUILDING BLOCKS
 
 
 
 
10.2.1.2
RESINS
 
 
 
 
 
 
 
 
10.2.1.2.1
BROADER LINKER CHEMISTRY AND HIGH-THROUGHPUT SPPS FORMATS TO SUPPORT STEADY RESIN DEMAND
 
 
 
 
10.2.1.3
COUPLING REAGENTS
 
 
 
 
 
 
 
 
10.2.1.3.1
NEED FOR FASTER ACTIVATION AND LOWER SIDE-REACTION RISK TO SUSTAIN DEMAND FOR ADVANCED COUPLING CHEMISTRY
 
 
 
 
10.2.1.4
PEPTIDE MODIFICATION REAGENTS
 
 
 
 
 
 
 
 
10.2.1.4.1
HALF-LIFE EXTENSION, TARGETING, AND CONJUGATION STRATEGIES TO MAKE MODIFICATION REAGENTS FASTEST-GROWING REAGENT CATEGORY
 
 
 
 
10.2.1.5
LABELING REAGENTS
 
 
 
 
 
 
 
 
10.2.1.5.1
RISING USE OF LABELED PEPTIDES IN IMAGING, DIAGNOSTICS, BINDING STUDIES, AND ASSAY DEVELOPMENT TO EXPAND DEMAND
 
 
 
 
10.2.1.6
PROTECTION & DEPROTECTION REAGENTS
 
 
 
 
 
 
 
 
10.2.1.6.1
ORTHOGONAL PROTECTING STRATEGIES AND PRESSURE TO REDUCE HAZARDOUS CHEMISTRY TO SHAPE PRODUCT SELECTION
 
 
 
 
10.2.1.7
CLEAVAGE REAGENTS
 
 
 
 
 
 
 
 
10.2.1.7.1
CONTINUED SPPS USE AND DEMAND FOR CLEANER CLEAVAGE PROFILES TO SUPPORT RECURRING CLEAVAGE-CHEMISTRY PURCHASES
 
 
 
 
10.2.1.8
OTHER REAGENTS
 
 
 
 
 
10.2.2
CONSUMABLES
 
 
 
 
 
 
 
10.2.2.1
HIGHER SYNTHESIS THROUGHPUT AND PURIFICATION WORKLOAD TO SUPPORT STEADY RECURRING CONSUMABLES DEMAND
 
 
 
 
10.3
INSTRUMENTS
 
 
 
 
 
 
 
10.3.1
PEPTIDE SYNTHESIZERS
 
 
 
 
 
 
 
10.3.1.1
PEPTIDE SYNTHESIZERS, BY TYPE
 
 
 
 
 
 
 
 
10.3.1.1.1
AUTOMATED PEPTIDE SYNTHESIZERS
 
 
 
 
 
 
10.3.1.1.2
MANUAL PEPTIDE SYNTHESIZERS
 
 
 
 
10.3.1.2
PEPTIDE SYNTHESIZERS, BY TECHNOLOGY
 
 
 
 
 
 
 
 
10.3.1.2.1
CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS
 
 
 
 
 
 
10.3.1.2.2
MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS
 
 
 
 
 
 
10.3.1.2.3
HYBRID PEPTIDE SYNTHESIZERS
 
 
 
 
 
 
10.3.1.2.4
OTHER PEPTIDE SYNTHESIZERS
 
 
 
10.3.2
PURIFICATION SYSTEMS
 
 
 
 
 
 
 
10.3.2.1
HIGHER CRUDE-PEPTIDE COMPLEXITY AND THROUGHPUT BOTTLENECKS TO INCREASE DEMAND FOR SCALABLE PURIFICATION PLATFORMS
 
 
 
 
 
10.3.3
ANALYTICAL & QUALITY CONTROL INSTRUMENTS
 
 
 
 
 
 
 
10.3.3.1
IMPURITY PROFILING, IDENTITY CONFIRMATION, AND TIGHTER PEPTIDE QUALITY REQUIREMENTS TO SUSTAIN ANALYTICAL PLATFORM INVESTMENT
 
 
 
 
 
10.3.4
LYOPHILIZATION EQUIPMENT
 
 
 
 
 
 
 
10.3.4.1
NEED FOR STABLE DRY PEPTIDE FORMATS AND SCALE-APPROPRIATE FREEZE-DRYING CAPACITY TO SUPPORT DEMAND
 
 
 
 
 
10.3.5
OTHER INSTRUMENTS
 
 
 
 
11
PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TECHNIQUE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 52 Data Tables
 
 
 
 
 
224
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
CHEMICAL SYNTHESIS
 
 
 
 
 
 
 
11.2.1
SOLID-PHASE PEPTIDE SYNTHESIS (SPPS)
 
 
 
 
 
 
 
11.2.1.1
AUTOMATION, RAPID ITERATIVE CHEMISTRY, AND COMMERCIAL-SCALE FAMILIARITY TO SUSTAIN SPPS AS LARGEST CHEMICAL SYNTHESIS METHOD
 
 
 
 
 
11.2.2
LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS)
 
 
 
 
 
 
 
11.2.2.1
SOLVENT-EFFICIENCY IMPROVEMENTS AND LARGE-SCALE ECONOMICS TO MAKE LPPS FASTEST-GROWING CHEMICAL SYNTHESIS METHOD
 
 
 
 
 
11.2.3
OTHER CHEMICAL METHODS
 
 
 
 
 
11.3
BIOLOGICAL SYNTHESIS
 
 
 
 
 
 
 
11.3.1
RECOMBINANT PEPTIDE PRODUCTION
 
 
 
 
 
 
 
11.3.1.1
SCALABLE MICROBIAL EXPRESSION AND ESTABLISHED BIOLOGICS INFRASTRUCTURE TO KEEP RECOMBINANT PRODUCTION DOMINANT WITHIN BIOLOGICAL SYNTHESIS
 
 
 
 
 
11.3.2
ENZYMATIC PEPTIDE SYNTHESIS
 
 
 
 
 
 
 
11.3.2.1
HIGH SELECTIVITY AND LOWER-SOLVENT LIGATION TO POSITION ENZYMATIC SYNTHESIS AS FASTEST-GROWING BIOLOGICAL METHOD
 
 
 
12
PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
 
 
 
 
 
251
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
12.2.1
EXPANDING PEPTIDE PIPELINES AND IN-HOUSE MANUFACTURING CAPABILITIES TO DRIVE MARKET GROWTH
 
 
 
 
 
12.3
CROS & CDMOS
 
 
 
 
 
 
 
12.3.1
RAPID OUTSOURCING AND CAPACITY EXPANSION TO MAKE CROS & CDMOS FASTEST-GROWING PRODUCT END-USER CATEGORY
 
 
 
 
 
12.4
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
 
12.4.1
DISCOVERY-LED PEPTIDE LIBRARIES AND GREATER ACCESS TO AUTOMATED BENCHTOP SYSTEMS TO SUSTAIN RESEARCH INSTITUTE DEMAND
 
 
 
 
 
12.5
MEDICAL DEVICE COMPANIES
 
 
 
 
 
 
 
12.5.1
PEPTIDE-FUNCTIONALIZED BIOSENSORS AND SURFACE-ENGINEERED DEVICES TO BROADEN SPECIALIZED DEMAND FOR MODIFIED SYNTHESIS PRODUCTS
 
 
 
 
 
12.6
CLINICAL & DIAGNOSTIC LABORATORIES
 
 
 
 
 
 
 
12.6.1
HIGHER ASSAY SPECIFICITY AND STANDARDIZED PEPTIDE REAGENTS TO SUPPORT ADOPTION IN CLINICAL AND DIAGNOSTIC LABORATORIES
 
 
 
 
13
PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
 
 
 
 
 
270
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
CUSTOM PEPTIDE SYNTHESIS SERVICES
 
 
 
 
 
 
 
13.2.1
FLEXIBLE SEQUENCE, PURITY, AND QUANTITY REQUIREMENTS TO KEEP CUSTOM PEPTIDE SYNTHESIS SERVICES LARGEST SERVICE CATEGORY
 
 
 
 
 
13.3
PEPTIDE ENGINEERING & MODIFICATION SERVICES
 
 
 
 
 
 
 
13.3.1
GROWING NEED FOR HALF-LIFE EXTENSION, TARGETING, AND CONJUGATION TO MAKE ENGINEERING & MODIFICATION SERVICES FASTEST-GROWING CATEGORY
 
 
 
 
 
13.4
PEPTIDE PURIFICATION SERVICES
 
 
 
 
 
 
 
13.4.1
MORE DIFFICULT PEPTIDE SEQUENCES AND TIGHTER PURITY SPECIFICATIONS TO SUSTAIN DEMAND FOR OUTSOURCED PURIFICATION
 
 
 
 
 
13.5
PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES
 
 
 
 
 
 
 
13.5.1
RISING MOLECULAR COMPLEXITY AND QUALITY EXPECTATIONS TO EXPAND PEPTIDE ANALYTICAL & CHARACTERIZATION OUTSOURCING
 
 
 
 
 
13.6
PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES
 
 
 
 
 
 
 
13.6.1
HIGH-THROUGHPUT SCREENING AND IMMUNE-MONITORING WORKFLOWS TO INCREASE ADOPTION OF PEPTIDE LIBRARY SERVICES
 
 
 
 
14
PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
 
 
 
 
 
289
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
14.2.1
BROAD OUTSOURCING ACROSS DISCOVERY AND DEVELOPMENT TO BOOST MARKET GROWTH
 
 
 
 
 
14.3
CROS & CDMOS
 
 
 
 
 
 
 
14.3.1
EXTERNAL CAPACITY, SPECIALIZED CHEMISTRY, AND NETWORK FLEXIBILITY TO MAKE CROS & CDMOS FASTEST-GROWING SERVICE END-USER CATEGORY
 
 
 
 
 
14.4
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
 
14.4.1
FLEXIBLE PROJECT-SCALE OUTSOURCING AND SPECIALIZED PEPTIDE FORMATS TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
14.5
MEDICAL DEVICE COMPANIES
 
 
 
 
 
 
 
14.5.1
PEPTIDE-FUNCTIONALIZED DEVICES AND BIOSENSORS TO INCREASE DEMAND FOR SPECIALIZED SYNTHESIS, MODIFICATION, AND CONJUGATION SERVICES
 
 
 
 
 
14.6
CLINICAL & DIAGNOSTIC LABORATORIES
 
 
 
 
 
 
 
14.6.1
ASSAY STANDARDIZATION AND CLINICAL-GRADE QUALITY REQUIREMENTS TO SUPPORT OUTSOURCED PEPTIDE SERVICES FOR DIAGNOSTIC LABORATORIES
 
 
 
 
15
PEPTIDE SYNTHESIS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 94 Data Tables
 
 
 
 
 
308
 
15.1
INTRODUCTION
 
 
 
 
 
 
15.2
THERAPEUTIC APPLICATIONS
 
 
 
 
 
 
 
15.2.1
THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION
 
 
 
 
 
 
 
15.2.1.1
DIABETES
 
 
 
 
 
 
 
 
15.2.1.1.1
LARGE ESTABLISHED PEPTIDE CLASSES AND SUSTAINED NEED FOR HIGH-PURITY ANALOGS DRIVE GROWTH
 
 
 
 
15.2.1.2
OBESITY
 
 
 
 
 
 
 
 
15.2.1.2.1
LATE-STAGE DUAL- AND TRIPLE-AGONIST PIPELINES AND RAPID COMMERCIAL SCALE-UP TO MAKE OBESITY FASTEST-GROWING THERAPEUTIC INDICATION
 
 
 
 
15.2.1.3
CANCER
 
 
 
 
 
 
 
 
15.2.1.3.1
TARGETED DELIVERY, NEOANTIGEN PROGRAMS, AND RADIOLIGAND DEVELOPMENT TO DEEPEN PEPTIDE-SYNTHESIS REQUIREMENTS IN ONCOLOGY
 
 
 
 
15.2.1.4
AUTOIMMUNE DISEASE
 
 
 
 
 
 
 
 
15.2.1.4.1
TARGETED ORAL PEPTIDES AND ANTIGEN-SPECIFIC IMMUNOMODULATION TO BROADEN PEPTIDE USE IN CHRONIC AUTOIMMUNE DISORDERS
 
 
 
 
15.2.1.5
OTHER THERAPEUTIC INDICATIONS
 
 
 
 
 
15.2.2
THERAPEUTIC APPLICATIONS, BY MOLECULE
 
 
 
 
 
 
 
15.2.2.1
METABOLIC & HORMONAL PEPTIDES
 
 
 
 
 
 
 
 
15.2.2.1.1
HIGH-VOLUME INCRETIN, INSULIN, AND HORMONE-PEPTIDE DEMAND TO DRIVE MARKET GROWTH
 
 
 
 
15.2.2.2
PEPTIDE INHIBITORS
 
 
 
 
 
 
 
 
15.2.2.2.1
IMPROVED ORAL DELIVERY, STRUCTURAL CONSTRAINT, AND ACCESS TO DIFFICULT PROTEIN INTERFACES TO EXPAND PEPTIDE INHIBITOR DEVELOPMENT
 
 
 
 
15.2.2.3
PEPTIDE-DRUG CONJUGATES (PDCS)
 
 
 
 
 
 
 
 
15.2.2.3.1
TARGETED PAYLOAD DELIVERY AND RADIOCONJUGATE PIPELINES TO MAKE PDCS FASTEST-GROWING THERAPEUTIC MOLECULE CATEGORY
 
 
 
 
15.2.2.4
PEPTIDE-BASED VACCINES
 
 
 
 
 
 
 
 
15.2.2.4.1
NEOEPITOPE DISCOVERY, IMMUNE MONITORING, AND PERSONALIZED VACCINE STRATEGIES TO SUPPORT HIGH-DIVERSITY PEPTIDE SYNTHESIS DEMAND
 
 
 
 
15.2.2.5
OTHER THERAPEUTIC MODALITIES
 
 
 
 
15.3
RESEARCH APPLICATIONS
 
 
 
 
 
 
 
15.3.1
HIGH-THROUGHPUT DISCOVERY, BIOMARKER STUDIES, AND RECURRING CUSTOM-PEPTIDE USE TO SUSTAIN BROAD RESEARCH DEMAND BASE
 
 
 
 
 
15.4
DIAGNOSTIC APPLICATIONS
 
 
 
 
 
 
 
15.4.1
PEPTIDE-BASED ASSAY REAGENTS, IMAGING LIGANDS, AND COMPANION-DIAGNOSTIC DEVELOPMENT TO EXPAND SPECIALIZED DIAGNOSTIC DEMAND
 
 
 
 
16
PEPTIDE SYNTHESIS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 455 Data Tables.
 
 
 
 
 
356
 
16.1
INTRODUCTION
 
 
 
 
 
 
16.2
NORTH AMERICA
 
 
 
 
 
 
 
16.2.1
US
 
 
 
 
 
 
 
16.2.1.1
DENSE PEPTIDE PIPELINES AND DOMESTIC CAPACITY TO SUSTAIN MARKET GROWTH
 
 
 
 
 
16.2.2
CANADA
 
 
 
 
 
 
 
16.2.2.1
BIOPHARMA MANUFACTURING INVESTMENT AND RESEARCH DEMAND TO SUPPORT STEADY EXPANSION
 
 
 
 
16.3
EUROPE
 
 
 
 
 
 
 
16.3.1
GERMANY
 
 
 
 
 
 
 
16.3.1.1
INTEGRATED PEPTIDE MANUFACTURING AND STRONG CHEMICAL SUPPLY CHAINS TO SUPPORT DEMAND
 
 
 
 
 
16.3.2
UK
 
 
 
 
 
 
 
16.3.2.1
RESEARCH INTENSITY AND DIAGNOSTIC PEPTIDE CAPABILITY TO SUPPORT SPECIALIZED DEMAND
 
 
 
 
 
16.3.3
FRANCE
 
 
 
 
 
 
 
16.3.3.1
EXPANDING SPPS CAPACITY TO STRENGTHEN COMMERCIAL PEPTIDE SUPPLY BASE
 
 
 
 
 
16.3.4
ITALY
 
 
 
 
 
 
 
16.3.4.1
INJECTABLE MANUFACTURING INTEGRATION TO SUPPORT PEPTIDE DEVELOPMENT-TO-PRODUCT WORKFLOWS
 
 
 
 
 
16.3.5
SPAIN
 
 
 
 
 
 
 
16.3.5.1
RESEARCH AND SPECIALTY-PHARMA ACTIVITY TO SUSTAIN DEMAND FOR IMPORTED SYNTHESIS SOLUTIONS
 
 
 
 
 
16.3.6
REST OF EUROPE
 
 
 
 
 
16.4
ASIA PACIFIC
 
 
 
 
 
 
 
16.4.1
CHINA
 
 
 
 
 
 
 
16.4.1.1
LARGE-SCALE TIDES CAPACITY AND DOMESTIC SUPPLIER DEPTH TO ACCELERATE MARKET EXPANSION
 
 
 
 
 
16.4.2
JAPAN
 
 
 
 
 
 
 
16.4.2.1
ADVANCED DRUG DISCOVERY AND SPECIALTY PEPTIDE INNOVATION TO SUSTAIN HIGH-VALUE DEMAND
 
 
 
 
 
16.4.3
INDIA
 
 
 
 
 
 
 
16.4.3.1
COST-EFFICIENT CRDMO EXPANSION AND NEW PEPTIDE CAPACITY TO ACCELERATE MARKET GROWTH
 
 
 
 
 
16.4.4
SOUTH KOREA
 
 
 
 
 
 
 
16.4.4.1
BIOTECH INVESTMENT AND LONG-ACTING PEPTIDE DEVELOPMENT TO EXPAND SPECIALIZED DEMAND
 
 
 
 
 
16.4.5
AUSTRALIA
 
 
 
 
 
 
 
16.4.5.1
RESEARCH-INTENSIVE INSTITUTIONS AND BIOTECH PIPELINES TO SUSTAIN HIGH-VALUE PEPTIDE DEMAND
 
 
 
 
 
16.4.6
REST OF ASIA PACIFIC
 
 
 
 
 
16.5
LATIN AMERICA
 
 
 
 
 
 
 
16.5.1
BRAZIL
 
 
 
 
 
 
 
16.5.1.1
LARGE RESEARCH BASE AND METABOLIC-DISEASE FOCUS TO MAKE BRAZIL CORE LATIN AMERICAN MARKET
 
 
 
 
 
16.5.2
MEXICO
 
 
 
 
 
 
 
16.5.2.1
US-LINKED MANUFACTURING AND CLINICAL RESEARCH TO SUPPORT PEPTIDE SYNTHESIS DEMAND
 
 
 
 
 
16.5.3
REST OF LATIN AMERICA
 
 
 
 
 
16.6
MIDDLE EAST
 
 
 
 
 
 
 
16.6.1
GCC COUNTRIES
 
 
 
 
 
 
 
16.6.1.1
SAUDI ARABIA
 
 
 
 
 
 
 
 
16.6.1.1.1
LOCALIZATION INITIATIVES AND RESEARCH FUNDING TO SUPPORT RISING PEPTIDE WORKFLOW ADOPTION
 
 
 
 
16.6.1.2
UAE
 
 
 
 
 
 
 
 
16.6.1.2.1
BIOTECH HUBS AND REGIONAL DISTRIBUTION TO STRENGTHEN ACCESS TO PEPTIDE SYNTHESIS SOLUTIONS
 
 
 
 
16.6.1.3
REST OF GCC COUNTRIES
 
 
 
 
 
16.6.2
REST OF MIDDLE EAST
 
 
 
 
 
16.7
AFRICA
 
 
 
 
 
 
 
16.7.1
RESEARCH-LED DEMAND AND IMPORT DEPENDENCE TO SHAPE MARKET
 
 
 
 
17
COMPETITIVE LANDSCAPE
Discover winning strategies and market dominance of key players in peptide synthesis by 2025.
 
 
 
 
 
556
 
17.1
OVERVIEW
 
 
 
 
 
 
17.2
KEY PLAYER STRATEGY/RIGHT TO WIN
 
 
 
 
 
 
 
17.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PEPTIDE SYNTHESIS MARKET
 
 
 
 
 
17.3
REVENUE ANALYSIS, 2021–2025
 
 
 
 
 
 
 
17.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
17.5
COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2025
 
 
 
 
 
 
 
17.5.1
STARS
 
 
 
 
 
 
17.5.2
EMERGING LEADERS
 
 
 
 
 
 
17.5.3
PERVASIVE PLAYERS
 
 
 
 
 
 
17.5.4
PARTICIPANTS
 
 
 
 
 
 
17.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
 
 
 
 
 
 
 
17.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
17.5.5.2
REGION FOOTPRINT
 
 
 
 
 
 
17.5.5.3
OFFERING FOOTPRINT
 
 
 
 
 
 
17.5.5.4
PRODUCT TYPE FOOTPRINT
 
 
 
 
 
 
17.5.5.5
APPLICATION FOOTPRINT
 
 
 
 
17.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
 
17.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
17.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
17.6.3
DYNAMIC COMPANIES
 
 
 
 
 
 
17.6.4
STARTING BLOCKS
 
 
 
 
 
 
17.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
17.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
17.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
17.7
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
 
 
17.7.1
FINANCIAL METRICS
 
 
 
 
 
 
17.7.2
COMPANY VALUATION
 
 
 
 
 
17.8
PRODUCT/SERVICE COMPARISON
 
 
 
 
 
 
17.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
17.9.1
PRODUCT LAUNCHES
 
 
 
 
 
 
17.9.2
DEALS
 
 
 
 
 
 
17.9.3
EXPANSIONS
 
 
 
 
18
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
577
 
18.1
KEY PLAYERS
 
 
 
 
 
 
 
18.1.1
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
 
18.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
18.1.1.2
PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
18.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
18.1.1.3.1
PRODUCT LAUNCHES
 
 
 
 
 
 
18.1.1.3.2
DEALS
 
 
 
 
 
 
18.1.1.3.3
EXPANSIONS
 
 
 
 
18.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
18.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
18.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
18.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
 
 
 
18.1.2
MERCK KGAA
 
 
 
 
 
 
18.1.3
AGILENT TECHNOLOGIES, INC.
 
 
 
 
 
 
18.1.4
GENSCRIPT BIOTECH CORPORATION
 
 
 
 
 
 
18.1.5
KANEKA CORPORATION
 
 
 
 
 
 
18.1.6
SARTORIUS AG
 
 
 
 
 
 
18.1.7
BACHEM HOLDING AG
 
 
 
 
 
 
18.1.8
BIOTAGE AB
 
 
 
 
 
 
18.1.9
CEM CORPORATION
 
 
 
 
 
 
18.1.10
BIO-SYNTHESIS, INC.
 
 
 
 
 
 
18.1.11
BIOSYNTH
 
 
 
 
 
 
18.1.12
CSBIO
 
 
 
 
 
 
18.1.13
GL BIOCHEM (SHANGHAI) LTD.
 
 
 
 
 
 
18.1.14
MESA LABORATORIES, INC.
 
 
 
 
 
 
18.1.15
DANAHER CORPORATION
 
 
 
 
 
18.2
OTHER PLAYERS
 
 
 
 
 
 
 
18.2.1
CHEM-IMPEX INTERNATIONAL, INC.
 
 
 
 
 
 
18.2.2
ADVANCED CHEMTECH
 
 
 
 
 
 
18.2.3
MIMOTOPES PTY LTD.
 
 
 
 
 
 
18.2.4
IRIS BIOTECH GMBH
 
 
 
 
 
 
18.2.5
AAPPTEC, LLC
 
 
 
 
 
 
18.2.6
ENAMINE LTD.
 
 
 
 
 
 
18.2.7
INTAVIS PEPTIDE SERVICES GMBH
 
 
 
 
 
 
18.2.8
JPT PEPTIDE TECHNOLOGIES GMBH
 
 
 
 
 
 
18.2.9
INNOVAGEN AB
 
 
 
 
 
 
18.2.10
PEPTIDE PROTEIN RESEARCH LTD.
 
 
 
 
 
 
18.2.11
LIFETEIN LLC
 
 
 
 
 
 
18.2.12
CREATIVE PEPTIDES
 
 
 
 
 
 
18.2.13
GENEMED SYNTHESIS, INC.
 
 
 
 
 
 
18.2.14
CHINAPEPTIDES CO., LTD.
 
 
 
 
 
 
18.2.15
BEIJING SCILIGHT BIOTECHNOLOGY LTD. CO.
 
 
 
 
19
RESEARCH METHODOLOGY
 
 
 
 
 
644
 
19.1
RESEARCH DATA
 
 
 
 
 
 
 
19.1.1
SECONDARY DATA
 
 
 
 
 
 
 
19.1.1.1
KEY SECONDARY SOURCES
 
 
 
 
 
 
19.1.1.2
KEY DATA FROM SECONDARY RESEARCH
 
 
 
 
 
19.1.2
PRIMARY DATA
 
 
 
 
 
 
 
19.1.2.1
KEY PRIMARY PARTICIPANTS
 
 
 
 
 
 
19.1.2.2
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
 
 
19.1.2.3
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
19.2
MARKET SIZE ESTIMATION
 
 
 
 
 
 
 
19.2.1
GLOBAL PEPTIDE SYNTHESIS MARKET ESTIMATION, 2025
 
 
 
 
 
 
 
19.2.1.1
APPROACH 1: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP)
 
 
 
 
 
 
19.2.1.2
APPROACH 2: PRIMARY RESEARCH
 
 
 
 
 
 
 
 
19.2.1.2.1
KEY INDUSTRY INSIGHTS
 
 
 
 
19.2.1.3
APPROACH 3: MNM REPOSITORY ANALYSIS
 
 
 
 
 
19.2.2
SEGMENTAL MARKET SIZE ESTIMATION, 2025
 
 
 
 
 
19.3
MARKET GROWTH RATE PROJECTIONS
 
 
 
 
 
 
19.4
DATA TRIANGULATION
 
 
 
 
 
 
19.5
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
19.6
RESEARCH LIMITATIONS & RISK ASSESSMENT
 
 
 
 
 
20
APPENDIX
 
 
 
 
 
657
 
20.1
DISCUSSION GUIDE
 
 
 
 
 
 
20.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
20.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
20.4
RELATED REPORTS
 
 
 
 
 
 
20.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
PEPTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS
 
 
 
 
 
 
TABLE 2
GLOBAL PEPTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
 
 
 
 
 
 
TABLE 3
LIST OF SOME LATE-STAGE PEPTIDE THERAPEUTICS
 
 
 
 
 
 
TABLE 4
PEPTIDE SYNTHESIS MARKET: IMPACT OF PORTER’S FIVE FORCES
 
 
 
 
 
 
TABLE 5
PEPTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM
 
 
 
 
 
 
TABLE 6
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 7
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 8
IMPORT DATA FOR HS CODE 902720, 2021–2025 (USD THOUSAND)
 
 
 
 
 
 
TABLE 9
IMPORT DATA FOR HS CODE 902720, 2021–2025 (UNITS)
 
 
 
 
 
 
TABLE 10
EXPORT DATA FOR HS CODE 902720, 2021–2025 (USD THOUSAND)
 
 
 
 
 
 
TABLE 11
EXPORT DATA FOR HS CODE 902720, 2021–2025 (TONS)
 
 
 
 
 
 
TABLE 12
IMPORT DATA FOR HS CODE 841933, 2022–2025 (USD THOUSAND)
 
 
 
 
 
 
TABLE 13
IMPORT DATA FOR HS CODE 841933, 2022–2025 (UNITS)
 
 
 
 
 
 
TABLE 14
EXPORT DATA FOR HS CODE 841933, 2022–2025 (USD THOUSAND)
 
 
 
 
 
 
TABLE 15
EXPORT DATA FOR HS CODE 841933, 2022–2025 (TONS)
 
 
 
 
 
 
TABLE 16
PEPTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
TABLE 17
PEPTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2026
 
 
 
 
 
 
TABLE 18
CASE STUDIES OF AI IMPLEMENTATION IN PEPTIDE SYNTHESIS MARKET
 
 
 
 
 
 
TABLE 19
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PEPTIDE SYNTHESIS
 
 
 
 
 
 
TABLE 20
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 21
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 22
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 23
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING TYPE (%)
 
 
 
 
 
 
TABLE 25
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
TABLE 26
PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 27
PEPTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 28
NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 29
EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 30
ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 31
LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 32
MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 33
GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 34
PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 35
NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 38
LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
EUROPE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 50
PEPTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
EUROPE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 56
GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
AMINO ACID BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
NORTH AMERICA: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
EUROPE: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
ASIA PACIFIC: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 62
LATIN AMERICA: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 63
MIDDLE EAST: AMINO ACID BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
GCC COUNTRIES: AMINO ACID BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
RESINS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 66
NORTH AMERICA: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
EUROPE: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 68
ASIA PACIFIC: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
LATIN AMERICA: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
MIDDLE EAST: RESINS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
GCC COUNTRIES: RESINS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 72
COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
NORTH AMERICA: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
EUROPE: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
ASIA PACIFIC: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
LATIN AMERICA: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
MIDDLE EAST: COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
GCC COUNTRIES: COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
PEPTIDE MODIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
NORTH AMERICA: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
EUROPE: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
ASIA PACIFIC: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
LATIN AMERICA: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
MIDDLE EAST: PEPTIDE MODIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
GCC COUNTRIES: PEPTIDE MODIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
LABELING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
NORTH AMERICA: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
EUROPE: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
ASIA PACIFIC: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 90
LATIN AMERICA: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
MIDDLE EAST: LABELING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
GCC COUNTRIES: LABELING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
PROTECTION & DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
NORTH AMERICA: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
EUROPE: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
ASIA PACIFIC: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
LATIN AMERICA: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
MIDDLE EAST: PROTECTION & DEPROTECTION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
GCC COUNTRIES: PROTECTION & DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
CLEAVAGE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
NORTH AMERICA: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
EUROPE: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
ASIA PACIFIC: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
LATIN AMERICA: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
MIDDLE EAST: CLEAVAGE REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
GCC COUNTRIES: CLEAVAGE REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
MIDDLE EAST: OTHER REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
NORTH AMERICA: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
EUROPE: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
ASIA PACIFIC: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
LATIN AMERICA: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
MIDDLE EAST: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
GCC COUNTRIES: PEPTIDE SYNTHESIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 121
PEPTIDE SYNTHESIS INSTRUMENTS: SELECTED PRODUCTS OFFERED BY KEY SUPPLIERS
 
 
 
 
 
 
TABLE 122
PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
NORTH AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
EUROPE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
ASIA PACIFIC: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
LATIN AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
MIDDLE EAST: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
GCC COUNTRIES: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
PEPTIDE SYNTHESIZERS: SELECTED PRODUCTS OFFERED BY KEY SUPPLIERS
 
 
 
 
 
 
TABLE 131
PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
NORTH AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 133
EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 139
PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
AUTOMATED PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
 
 
 
 
 
 
TABLE 141
AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
NORTH AMERICA: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
EUROPE: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
ASIA PACIFIC: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
LATIN AMERICA: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
MIDDLE EAST: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
GCC COUNTRIES: AUTOMATED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
MANUAL PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
 
 
 
 
 
 
TABLE 149
MANUAL PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
NORTH AMERICA: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 151
EUROPE: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
ASIA PACIFIC: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
LATIN AMERICA: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
MIDDLE EAST: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
GCC COUNTRIES: MANUAL PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 156
CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
 
 
 
 
 
 
TABLE 157
CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
NORTH AMERICA: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
EUROPE: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
ASIA PACIFIC: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
LATIN AMERICA: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
MIDDLE EAST: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 163
GCC COUNTRIES: CONVENTIONAL-BATCH PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS: SELECTED PRODUCT EXAMPLES
 
 
 
 
 
 
TABLE 165
MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
NORTH AMERICA: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
EUROPE: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
ASIA PACIFIC: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 169
LATIN AMERICA: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
MIDDLE EAST: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
GCC COUNTRIES: MICROWAVE-ASSISTED PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
HYBRID PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
NORTH AMERICA: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
EUROPE: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 175
ASIA PACIFIC: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
LATIN AMERICA: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
MIDDLE EAST: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
GCC COUNTRIES: HYBRID PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
OTHER PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
NORTH AMERICA: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 181
EUROPE: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
ASIA PACIFIC: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
LATIN AMERICA: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
MIDDLE EAST: OTHER PEPTIDE SYNTHESIZERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 185
GCC COUNTRIES: OTHER PEPTIDE SYNTHESIZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
PURIFICATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 187
NORTH AMERICA: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
EUROPE: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
ASIA PACIFIC: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
LATIN AMERICA: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 191
MIDDLE EAST: PURIFICATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
GCC COUNTRIES: PURIFICATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 193
ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
NORTH AMERICA: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
EUROPE: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
ASIA PACIFIC: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 197
LATIN AMERICA: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
MIDDLE EAST: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
GCC COUNTRIES: ANALYTICAL & QUALITY CONTROL INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
LYOPHILIZATION EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
NORTH AMERICA: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
EUROPE: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 203
ASIA PACIFIC: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
LATIN AMERICA: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
MIDDLE EAST: LYOPHILIZATION EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
GCC COUNTRIES: LYOPHILIZATION EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
NORTH AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 209
EUROPE: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 210
ASIA PACIFIC: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 211
LATIN AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
MIDDLE EAST: OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
GCC COUNTRIES: OTHER INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
CHEMICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
CHEMICAL PEPTIDE SYNTHESIS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
NORTH AMERICA: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
EUROPE: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
ASIA PACIFIC: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
LATIN AMERICA: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
MIDDLE EAST: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
GCC COUNTRIES: SOLID-PHASE PEPTIDE SYNTHESIS (SPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
NORTH AMERICA: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
EUROPE: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
ASIA PACIFIC: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
LATIN AMERICA: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
MIDDLE EAST: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
GCC COUNTRIES: LIQUID-PHASE PEPTIDE SYNTHESIS (LPPS) MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 239
EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET FOR OTHER CHEMICAL METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
NORTH AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
EUROPE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
ASIA PACIFIC: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
LATIN AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
MIDDLE EAST: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
GCC COUNTRIES: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
RECOMBINANT PEPTIDE PRODUCTION MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
NORTH AMERICA: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
EUROPE: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
ASIA PACIFIC: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
LATIN AMERICA: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
MIDDLE EAST: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
GCC COUNTRIES: RECOMBINANT PEPTIDE PRODUCTION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
NORTH AMERICA: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
EUROPE: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
ASIA PACIFIC: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
LATIN AMERICA: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
MIDDLE EAST: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
GCC COUNTRIES: ENZYMATIC PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 268
NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 274
PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 278
LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 280
GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
NORTH AMERICA: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
EUROPE: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
ASIA PACIFIC: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
LATIN AMERICA: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 308
MIDDLE EAST: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
GCC COUNTRIES: CUSTOM PEPTIDE SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
NORTH AMERICA: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
EUROPE: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
ASIA PACIFIC: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 314
LATIN AMERICA: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
MIDDLE EAST: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
GCC COUNTRIES: PEPTIDE ENGINEERING & MODIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
PEPTIDE PURIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
NORTH AMERICA: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
EUROPE: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 320
ASIA PACIFIC: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 321
LATIN AMERICA: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
MIDDLE EAST: PEPTIDE PURIFICATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
GCC COUNTRIES: PEPTIDE PURIFICATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
NORTH AMERICA: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
EUROPE: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 327
ASIA PACIFIC: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
LATIN AMERICA: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
MIDDLE EAST: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
GCC COUNTRIES: PEPTIDE ANALYTICAL & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
NORTH AMERICA: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 333
EUROPE: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
ASIA PACIFIC: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
LATIN AMERICA: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
MIDDLE EAST: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
GCC COUNTRIES: PEPTIDE LIBRARY PREPARATION/SYNTHESIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 339
PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 342
ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 345
GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 351
MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 357
LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 363
ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 370
ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
EUROPE: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
EUROPE: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 394
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 395
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 396
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR OBESITY APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 397
PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 398
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 399
EUROPE: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 400
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 401
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 402
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 403
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 404
PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 405
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 406
EUROPE: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 407
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 408
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 409
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 410
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR AUTOIMMUNE DISEASE APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 411
PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 412
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 413
EUROPE: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 414
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 415
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 416
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 417
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 418
PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 419
PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 420
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 421
EUROPE: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 422
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 423
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 424
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 425
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR METABOLIC & HORMONAL PEPTIDES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 426
PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 427
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 428
EUROPE: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 429
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 430
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 431
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 432
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE INHIBITORS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 433
PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 434
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 435
EUROPE: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 436
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 437
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 438
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 439
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-DRUG CONJUGATES (PDCS), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 440
PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 441
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 442
EUROPE: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 443
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 444
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 445
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 446
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR PEPTIDE-BASED VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 447
PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 448
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 449
EUROPE: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 450
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 451
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 452
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 453
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR OTHER THERAPEUTIC MODALITIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 454
PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 455
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 456
EUROPE: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 457
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 458
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 459
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 460
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 461
PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 462
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 463
EUROPE: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 464
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 465
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 466
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 467
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 468
PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 469
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 470
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 471
NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 472
NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 473
NORTH AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 474
NORTH AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 475
NORTH AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 476
NORTH AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 477
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 478
NORTH AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 479
NORTH AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 480
NORTH AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 481
NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 482
NORTH AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 483
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 484
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 485
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 486
US: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 487
US: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 488
US: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 489
US: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 490
US: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 491
US: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 492
US: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 493
US: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 494
US: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 495
US: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 496
US: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 497
US: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 498
US: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 499
US: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 500
US: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 501
US: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 502
CANADA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 503
CANADA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 504
CANADA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 505
CANADA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 506
CANADA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 507
CANADA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 508
CANADA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 509
CANADA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 510
CANADA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 511
CANADA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 512
CANADA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 513
CANADA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 514
CANADA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 515
CANADA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 516
CANADA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 517
CANADA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 518
EUROPE: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 519
EUROPE: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 520
EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 521
EUROPE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 522
EUROPE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 523
EUROPE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 524
EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 525
EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 526
EUROPE: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 527
EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 528
EUROPE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 529
EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 530
EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 531
EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 532
EUROPE: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 533
EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 534
EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 535
GERMANY: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 536
GERMANY: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 537
GERMANY: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 538
GERMANY: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 539
GERMANY: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 540
GERMANY: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 541
GERMANY: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 542
GERMANY: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 543
GERMANY: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 544
GERMANY: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 545
GERMANY: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 546
GERMANY: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 547
GERMANY: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 548
GERMANY: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 549
GERMANY: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 550
GERMANY: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 551
UK: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 552
UK: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 553
UK: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 554
UK: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 555
UK: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 556
UK: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 557
UK: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 558
UK: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 559
UK: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 560
UK: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 561
UK: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 562
UK: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 563
UK: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 564
UK: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 565
UK: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 566
UK: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 567
FRANCE: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 568
FRANCE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 569
FRANCE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 570
FRANCE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 571
FRANCE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 572
FRANCE: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 573
FRANCE: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 574
FRANCE: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 575
FRANCE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 576
FRANCE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 577
FRANCE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 578
FRANCE: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 579
FRANCE: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 580
FRANCE: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 581
FRANCE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 582
FRANCE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 583
ITALY: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 584
ITALY: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 585
ITALY: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 586
ITALY: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 587
ITALY: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 588
ITALY: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 589
ITALY: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 590
ITALY: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 591
ITALY: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 592
ITALY: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 593
ITALY: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 594
ITALY: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 595
ITALY: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 596
ITALY: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 597
ITALY: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 598
ITALY: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 599
SPAIN: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 600
SPAIN: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 601
SPAIN: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 602
SPAIN: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 603
SPAIN: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 604
SPAIN: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 605
SPAIN: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 606
SPAIN: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 607
SPAIN: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 608
SPAIN: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 609
SPAIN: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 610
SPAIN: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 611
SPAIN: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 612
SPAIN: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 USD MILLION)
 
 
 
 
 
 
TABLE 613
SPAIN: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 614
SPAIN: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 615
REST OF EUROPE: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 616
REST OF EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 617
REST OF EUROPE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 618
REST OF EUROPE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 619
REST OF EUROPE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 620
REST OF EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 621
REST OF EUROPE: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 622
REST OF EUROPE: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 623
REST OF EUROPE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 624
REST OF EUROPE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 625
REST OF EUROPE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 626
REST OF EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 627
REST OF EUROPE: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 628
REST OF EUROPE: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 629
REST OF EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 630
REST OF EUROPE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 631
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 632
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 633
ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 634
ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 635
ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 636
ASIA PACIFIC: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 637
ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 638
ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 639
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 640
ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 641
ASIA PACIFIC: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 642
ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 643
ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 644
ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 645
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 646
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 647
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 648
CHINA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 649
CHINA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 650
CHINA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 651
CHINA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 652
CHINA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 653
CHINA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 654
CHINA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 655
CHINA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 656
CHINA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 657
CHINA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 658
CHINA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 659
CHINA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 660
CHINA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 661
CHINA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 662
CHINA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 663
CHINA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 664
JAPAN: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 665
JAPAN: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 666
JAPAN: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 667
JAPAN: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 668
JAPAN: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 669
JAPAN: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 670
JAPAN: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 671
JAPAN: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 672
JAPAN: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 673
JAPAN: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 674
JAPAN: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 675
JAPAN: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 676
JAPAN: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 677
JAPAN: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 678
JAPAN: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 679
JAPAN: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 680
INDIA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 681
INDIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 682
INDIA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 683
INDIA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 684
INDIA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 685
INDIA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 686
INDIA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 687
INDIA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 688
INDIA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 689
INDIA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 690
INDIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 691
INDIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 692
INDIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 693
INDIA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 694
INDIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 695
INDIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 696
SOUTH KOREA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 697
SOUTH KOREA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 698
SOUTH KOREA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 699
SOUTH KOREA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 700
SOUTH KOREA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 701
SOUTH KOREA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 702
SOUTH KOREA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 703
SOUTH KOREA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 704
SOUTH KOREA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 705
SOUTH KOREA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 706
SOUTH KOREA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 707
SOUTH KOREA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 708
SOUTH KOREA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 709
SOUTH KOREA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 710
SOUTH KOREA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 711
SOUTH KOREA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 712
AUSTRALIA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 713
AUSTRALIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 714
AUSTRALIA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 715
AUSTRALIA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 716
AUSTRALIA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 717
AUSTRALIA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 718
AUSTRALIA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 719
AUSTRALIA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 720
AUSTRALIA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 721
AUSTRALIA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 722
AUSTRALIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 723
AUSTRALIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 724
AUSTRALIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 725
AUSTRALIA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 726
AUSTRALIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 727
AUSTRALIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 728
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 729
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 730
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 731
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 732
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 733
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 734
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 735
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 736
REST OF ASIA PACIFIC: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 737
REST OF ASIA PACIFIC: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 738
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 739
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 740
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 741
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 742
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 743
REST OF ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 744
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 745
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 746
LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 747
LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 748
LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 749
LATIN AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 750
LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 751
LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 752
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 753
LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 754
LATIN AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 755
LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 756
LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 757
LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 758
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 759
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 760
LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 761
BRAZIL: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 762
BRAZIL: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 763
BRAZIL: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 764
BRAZIL: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 765
BRAZIL: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 766
BRAZIL: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 767
BRAZIL: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 768
BRAZIL: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 769
BRAZIL: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 770
BRAZIL: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 771
BRAZIL: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 772
BRAZIL: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 773
BRAZIL: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 774
BRAZIL: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 775
BRAZIL: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 776
BRAZIL: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 777
MEXICO: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 778
MEXICO: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 779
MEXICO: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 780
MEXICO: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 781
MEXICO: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 782
MEXICO: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 783
MEXICO: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 784
MEXICO: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 785
MEXICO: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 786
MEXICO: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 787
MEXICO: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 788
MEXICO: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 789
MEXICO: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 790
MEXICO: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 791
MEXICO: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 792
MEXICO: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 793
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 794
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 795
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 796
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 797
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 798
REST OF LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 799
REST OF LATIN AMERICA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 800
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 801
REST OF LATIN AMERICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 802
REST OF LATIN AMERICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 803
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 804
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 805
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 806
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 807
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 808
REST OF LATIN AMERICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 809
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 810
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 811
MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 812
MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 813
MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 814
MIDDLE EAST: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 815
MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 816
MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 817
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 818
MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 819
MIDDLE EAST: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 820
MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 821
MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 822
MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 823
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 824
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 825
MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 826
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 827
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 828
GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 829
GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 830
GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 831
GCC COUNTRIES: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 832
GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 833
GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 834
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 835
GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 836
GCC COUNTRIES: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 837
GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 838
GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 839
GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 840
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 841
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 842
GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 843
SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 844
SAUDI ARABIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 845
SAUDI ARABIA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 846
SAUDI ARABIA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 847
SAUDI ARABIA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 848
SAUDI ARABIA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 849
SAUDI ARABIA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 850
SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 851
SAUDI ARABIA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 852
SAUDI ARABIA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 853
SAUDI ARABIA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 854
SAUDI ARABIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 855
SAUDI ARABIA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 856
SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 857
SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 858
SAUDI ARABIA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 859
UAE: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 860
UAE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 861
UAE: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 862
UAE: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 863
UAE: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 864
UAE: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 865
UAE: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 866
UAE: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 867
UAE: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 868
UAE: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 869
UAE: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 870
UAE: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 871
UAE: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 872
UAE: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 873
UAE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 874
UAE: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 875
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 876
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 877
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 878
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 879
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 880
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 881
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 882
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 883
REST OF GCC COUNTRIES: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 884
REST OF GCC COUNTRIES: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 885
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 886
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 887
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 888
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 889
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 890
REST OF GCC COUNTRIES: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 891
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 892
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 893
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 894
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 895
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 896
REST OF MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 897
REST OF MIDDLE EAST: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 898
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 899
REST OF MIDDLE EAST: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 900
REST OF MIDDLE EAST: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 901
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 902
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 903
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 904
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 905
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 906
REST OF MIDDLE EAST: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 907
AFRICA: PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 908
AFRICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 909
AFRICA: PEPTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 910
AFRICA: PEPTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 911
AFRICA: PEPTIDE SYNTHESIS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 912
AFRICA: PEPTIDE SYNTHESIZERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 913
AFRICA: PEPTIDE SYNTHESIZERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 914
AFRICA: PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 915
AFRICA: CHEMICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 916
AFRICA: BIOLOGICAL PEPTIDE SYNTHESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 917
AFRICA: PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 918
AFRICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 919
AFRICA: PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 920
AFRICA: PEPTIDE SYNTHESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 921
AFRICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 922
AFRICA: PEPTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY MOLECULE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 923
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET
 
 
 
 
 
 
TABLE 924
PEPTIDE SYNTHESIS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 925
PEPTIDE SYNTHESIS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 926
PEPTIDE SYNTHESIS MARKET: OFFERING FOOTPRINT
 
 
 
 
 
 
TABLE 927
PEPTIDE SYNTHESIS MARKET: PRODUCT TYPE FOOTPRINT
 
 
 
 
 
 
TABLE 928
PEPTIDE SYNTHESIS MARKET: APPLICATION FOOTPRINT
 
 
 
 
 
 
TABLE 929
PEPTIDE SYNTHESIS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
 
 
 
 
 
 
TABLE 930
PEPTIDE SYNTHESIS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY OFFERING AND REGION
 
 
 
 
 
 
TABLE 931
PEPTIDE SYNTHESIS MARKET: PRODUCT LAUNCHES, JANUARY 2023– AUGUST 2026
 
 
 
 
 
 
TABLE 932
PEPTIDE SYNTHESIS MARKET: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 933
PEPTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 934
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 935
THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 936
THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023– AUGUST 2026
 
 
 
 
 
 
TABLE 937
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 938
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 939
MERCK KGAA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 940
MERCK KGAA: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 941
MERCK KGAA: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 942
MERCK KGAA: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 943
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 944
AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 945
AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2023– AUGUST 2026
 
 
 
 
 
 
TABLE 946
GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 947
GENSCRIPT BIOTECH CORPORATION: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 948
GENSCRIPT BIOTECH CORPORATION: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 949
KANEKA CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 950
KANEKA CORPORATION: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 951
KANEKA CORPORATION: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 952
SARTORIUS AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 953
SARTORIUS AG: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 954
SARTORIUS AG: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 955
BACHEM HOLDING AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 956
BACHEM HOLDING AG: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 957
BACHEM HOLDING AG: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 958
BACHEM HOLDING AG: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 959
BIOTAGE AB: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 960
BIOTAGE AB: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 961
BIOTAGE AB: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 962
BIOTAGE AB: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 963
CEM CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 964
CEM CORPORATION: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 965
CEM CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 966
BIO-SYNTHESIS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 967
BIO-SYNTHESIS, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 968
BIOSYNTH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 969
BIOSYNTH: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 970
BIOSYNTH: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 971
BIOSYNTH: EXPANSIONS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 972
CSBIO: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 973
CSBIO: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 974
GL BIOCHEM (SHANGHAI) LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 975
GL BIOCHEM (SHANGHAI) LTD.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 976
MESA LABORATORIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 977
MESA LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 978
MESA LABORATORIES, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 979
MESA LABORATORIES, INC.: DEALS, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 980
DANAHER CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 981
DANAHER CORPORATION: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 982
DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026
 
 
 
 
 
 
TABLE 983
CHEM-IMPEX INTERNATIONAL, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 984
ADVANCED CHEMTECH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 985
MIMOTOPES PTY LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 986
IRIS BIOTECH GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 987
AAPPTEC, LLC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 988
ENAMINE LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 989
INTAVIS PEPTIDE SERVICES GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 990
JPT PEPTIDE TECHNOLOGIES GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 991
INNOVAGEN AB: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 992
PEPTIDE PROTEIN RESEARCH LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 993
LIFETEIN LLC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 994
CREATIVE PEPTIDES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 995
GENEMED SYNTHESIS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 996
CHINAPEPTIDES CO., LTD. (QYAOBIO): COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 997
BEIJING SCILIGHT BIOTECHNOLOGY LTD. CO.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 998
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
 
 
 
 
 
 
TABLE 999
RISK ASSESSMENT
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
PEPTIDE SYNTHESIS MARKET SEGMENTATION & REGIONAL SCOPE
 
 
 
 
 
 
FIGURE 2
PEPTIDE SYNTHESIS MARKET: YEARS CONSIDERED
 
 
 
 
 
 
FIGURE 3
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 4
GLOBAL PEPTIDE SYNTHESIS MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 6
DISRUPTIONS INFLUENCING GROWTH OF PEPTIDE SYNTHESIS MARKET
 
 
 
 
 
 
FIGURE 7
HIGH-GROWTH SEGMENTS IN PEPTIDE SYNTHESIS MARKET, 2026–2031
 
 
 
 
 
 
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PEPTIDE SYNTHESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 9
SURGING DEMAND FOR GLP-1 AND OTHER PEPTIDE THERAPEUTICS TO DRIVE MARKET GROWTH
 
 
 
 
 
 
FIGURE 10
PRODUCTS ACCOUNTED FOR LARGEST SHARE OF PEPTIDE SYNTHESIS MARKET IN NORTH AMERICA IN 2025
 
 
 
 
 
 
FIGURE 11
CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL PEPTIDE SYNTHESIS MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
THERAPEUTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 13
PEPTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 14
PEPTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 15
PEPTIDE SYNTHESIS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 16
PEPTIDE SYNTHESIS MARKET ECOSYSTEM
 
 
 
 
 
 
FIGURE 17
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY TYPE, 2023–2025 (USD)
 
 
 
 
 
 
FIGURE 18
AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
 
 
 
 
 
 
FIGURE 19
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
FIGURE 20
TOP APPLICANTS/OWNERS (COMPANIES) FOR PEPTIDE SYNTHESIS PATENTS, 2015–2025
 
 
 
 
 
 
FIGURE 21
IMPACT OF AI/GEN AI ON PEPTIDE SYNTHESIS MARKET
 
 
 
 
 
 
FIGURE 22
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
 
 
 
 
 
 
FIGURE 23
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
FIGURE 24
NORTH AMERICA: PEPTIDE SYNTHESIS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 25
ASIA PACIFIC: PEPTIDE SYNTHESIS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 26
REVENUE ANALYSIS OF KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2021–2025 (USD MILLION)
 
 
 
 
 
 
FIGURE 27
MARKET SHARE ANALYSIS OF KEY PLAYERS IN PEPTIDE SYNTHESIS MARKET, 2025
 
 
 
 
 
 
FIGURE 28
PEPTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 29
PEPTIDE SYNTHESIS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 30
PEPTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 31
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 32
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 33
PEPTIDE SYNTHESIS MARKET: PRODUCT/SERVICE COMPARATIVE ANALYSIS
 
 
 
 
 
 
FIGURE 34
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 35
MERCK KGAA: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 36
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 37
GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 38
KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 39
SARTORIUS AG: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 40
BACHEM HOLDING AG: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 41
MESA LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 42
DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 43
PEPTIDE SYNTHESIS MARKET: RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 44
PEPTIDE SYNTHESIS MARKET: BREAKDOWN OF PRIMARIES
 
 
 
 
 
 
FIGURE 45
GLOBAL PEPTIDE SYNTHESIS MARKET ESTIMATION, 2025
 
 
 
 
 
 
FIGURE 46
PEPTIDE SYNTHESIS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
 
 
 
 
 
 
FIGURE 47
ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE ANALYSIS (2025)
 
 
 
 
 
 
FIGURE 48
PEPTIDE SYNTHESIS MARKET: INSIGHTS FROM PRIMARIES
 
 
 
 
 
 
FIGURE 49
SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 50
PEPTIDE SYNTHESIS MARKET: CAGR PROJECTIONS
 
 
 
 
 
 
FIGURE 51
PEPTIDE SYNTHESIS MARKET: DATA TRIANGULATION
 
 
 
 
 
 

Methodology

This research study relied extensively on secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global peptide synthesis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the peptide synthesis market. The secondary sources used for this study include US Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), European Directorate for the Quality of Medicines & HealthCare (EDQM), Japan Pharmaceuticals and Medical Devices Agency (PMDA), World Health Organization (WHO), US Pharmacopeia (USP), ClinicalTrials.gov, Journal of Peptide Science, International Journal of Peptide Research and Therapeutics, Peptide Science, American Peptide Society (APS), European Peptide Society (EPS), Chemical & Engineering News (C&EN), Genetic Engineering & Biotechnology News (GEN), and BioPharm International; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations, among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess the market's future prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Peptide Synthesis Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the peptide synthesis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following.

Peptide Synthesis Market : Top-Down and Bottom-Up Approach

Peptide Synthesis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Peptide synthesis is the process of producing peptides through the controlled assembly of amino acids into specific sequences using chemical, biological, or hybrid manufacturing approaches.

The peptide synthesis market comprises the global commercial market for products and services used to chemically or biologically synthesize, modify, purify, and characterize peptides for research, drug discovery and development, diagnostics, therapeutics, and other life science applications. The market includes peptide synthesis instruments and systems, synthesis reagents and building blocks, purification and analytical instruments, synthesis-related consumables, and custom peptide synthesis services. Services covered include custom peptide synthesis, peptide engineering and modification, peptide labeling and conjugation, peptide purification, and peptide-specific analytical and characterization services provided by CROs, CDMOs and specialized peptide service providers.

Key Stakeholders

  • Peptide synthesis instrument manufacturers
  • Peptide synthesis reagent and consumable suppliers
  • Custom peptide synthesis and specialized peptide service providers
  • Pharmaceutical & biotechnology companies
  • Contract research organizations (CROs) & contract development and manufacturing organizations (CDMOs)
  • Academic & research institutes
  • Medical device companies
  • Clinical & diagnostic laboratories
  • Market research & consulting firms
  • Regulatory bodies

Report Objectives

  • To define, describe, and forecast the global peptide synthesis market based on offering, product type, technique, service type, application, product end user, service end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall peptide synthesis market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically profile the key players and comprehensively analyze their product & service portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product & service launches, expansions, and R&D activities in the peptide synthesis market
  • To analyze and provide funding & investment activities, brand/product/service comparative analysis, and vendor valuation & financial metrics of the peptide synthesis market

Available customizations:

Based on the given market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following customization options are available for this report:

Portfolio Assessment

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top four companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Geographical Analysis

  • A further breakdown of the Rest of Europe peptide synthesis market, by country
  • A further breakdown of the Rest of Asia Pacific peptide synthesis market, by country
  • A further breakdown of the Rest of Latin America peptide synthesis market, by country

Table of Contents

Methodology

 Request Customization Speak to Analyst
Speak to Analyst
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Peptide Synthesis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Peptide Synthesis Market

DMCA.com Protection Status
popup img